| Trial ID: | L3902 |
| Source ID: | NCT02545738
|
| Associated Drug: |
Liraglutide
|
| Title: |
Antiproteinuric Effects of Liraglutide Treatment
|
| Acronym: |
LIRALBU
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetic Kidney Disease
|
| Interventions: |
DRUG: Liraglutide|DRUG: placebo
|
| Outcome Measures: |
Primary: Change in albuminuria, 24h urinary albumin excretion rate (UAER mg/24h), 24 weeks | Secondary: Change in renin-angiotensin system hormones, renin (activity and concentration), angiotensin 1+2, aldosteron (concentrations), 24 weeks|Change in kidney function, Cr-EDTA-GFR (ml/min/1.73m2), 24 weeks|Change in 24h blood pressure, 24 h systolic and diastolic blood presure (mmHg), 24 weeks|Change in markers of inflammation, TNF-alfa, mcp (concentration), 24 weeks|24h heart rate, puls in BPM, 24 weeks
|
| Sponsor/Collaborators: |
Sponsor: Steno Diabetes Center Copenhagen | Collaborators: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
32
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2015-04
|
| Completion Date: |
2016-05
|
| Results First Posted: |
|
| Last Update Posted: |
2016-08-10
|
| Locations: |
Peter Rossing, Gentofte, 2820, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT02545738
|
